Despite the great progress which has been made in lung cancer treatment, particularly in receptor tyrosine kinase inhibition-based targeted therapy and immune checkpoint blockade-based cancer immunotherapy, lung cancer survival has remained poor over the past two decades. This evidence concerns the gene NTRK1 and lung carcinoma.